Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Pills are just as effective as intravenous (IV) injections in tackling bone infections, a study led by Oxford-based researchers has found.

The findings, published in The New England Journal of Medicine, challenge the long-held belief that injections into the vein are the best way to give antibiotics for bone and joint infections, such as infected hip or knee replacements.

They raise hopes that patients could go home sooner, reducing NHS costs.

The study run within the Surgical Intervention Trials Unit, led by Oxford University Hospitals (OUH) NHS Foundation Trust and supported by the National Institute for Health Research Oxford Biomedical Research Centre, recruited more than 1,000 people with bone or joint infection and randomly allocated them to injection or tablet antibiotics. In most cases, patients underwent surgery as well.

Bone and joint infections, which are commonly caused by bacteria such as staphylococcus (including MRSA) and streptococcus, are often painful, protracted and disabling.

As well as the inconvenience for patients having to stay in hospital or relying on a specialist nurse to visit the patient at home to administer intravenous antibiotics, injections pose a risk to patients as they can be complicated by infection or blood clots.

The study at 26 UK hospitals found little difference in the failure rate of antibiotics between pills or injections given for the first six weeks of treatment.

It found the median length of stay in hospital was 14 days for injections and 11 days for people who took the antibiotics in pill form.

Complications were less common in patients treated by tablets and the treatment costs were £2,740 cheaper than injections.

Chief investigator Dr Matthew Scarborough, OUH Consultant in Infectious Diseases and General Medicine, said: “For decades bone and joint infections have been treated primarily through intravenous antibiotics. This is inconvenient for the patient and costly for the health service.

“Our results are good news for the NHS as use of tablet antibiotics will save money whilst helping to prevent antibiotic resistance. It’s also great news for patients because we now know that changing how we give antibiotics can reduce risk, improve safety and give people more control over their treatment.”

The trial was supported by the NIHR Local Clinical Research network for Thames Valley and South Midlands, and involved members of OUH’s infectious diseases and orthopaedic departments.

Find out more

 

 

SITU logo

 

OVIVA logo

 

Similar stories

Fiona Powrie honoured by British Society for Immunology

Fiona Powrie was one of four researchers from the University of Oxford recognised for their outstanding contributions to immunology with Honorary Lifetime Membership of the British Society for Immunology.

The Kennedy Institute scoops sustainability award

A new roof extension was awarded the 2021 Green Award for Sustainability by the Oxford Preservation Trust alongside a Certificate in the New Building category.

Vaccination safety: generating accurate evidence is the clearest path to creating public trust

A new study shows that a vaccine surveillance method in observational data may generate high number of false positives

Fiona Powrie appointed new Deputy Chair of Wellcome’s Board of Governors

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

A drug being trialled to treat cancer, could be the key to reducing gut inflammation

Published in Nature Communications, a new study reveals a new signalling pathway behind macrophage inflammatory activity

Single-cell ancestry vaccine research funded by the Chan Zuckerberg Initiative

The Chan Zuckerberg Initiative (CZI) has provided $2 million in funding to investigate how our ancestry and diversity influence the way that vaccines work in our cells.